Nasdaq

PDS Biotechnology Corp

Pharmaceutical PreparationsCIK 0001472091Princeton, New JerseyFilings at SEC EDGAR

At a glance

Most recent filing on October 21, 2026 — a grant by Dawson John Andrew on Oct 18, 2026.

We hold 3 Form 4 lines, going back to October 20, 2026.

Insider trades

All 3 shown

This page is free to read, and it stops after 3 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Dawson John Andrew Director
22,700 sharesGrant
TradedOct 18, 2026FiledOct 21, 2026
Ramsdell Deborah Director
22,700 sharesGrant
TradedOct 18, 2026FiledOct 20, 2026
Wendel Bruce Director
22,700 sharesGrant
TradedOct 18, 2026FiledOct 20, 2026

CEO pay

What the company reported for its principal executive officer, usually the CEO, in the pay-versus-performance table of its proxy statement. The total counts shares and options at their value on the day they were granted. Actually paid counts them at the change in their value during the year, so it can be far higher or lower than the total, and negative. A dash means the company reported no amount.

Dr. Bedu-Addo, fiscal year ended Dec 31, 2025: total $828,307, actually paid $630,194. First reported Jun 26, 2026.

Earlier fiscal years are part of the subscription.